Trials / Conditions / Refractory Nodal Marginal Zone Lymphoma
Refractory Nodal Marginal Zone Lymphoma
6 registered clinical trials studyying Refractory Nodal Marginal Zone Lymphoma — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minoritie NCT06859008 | City of Hope Medical Center | Phase 1 |
| Recruiting | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for NCT06905509 | Joseph Tuscano | Phase 2 |
| Withdrawn | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683 | Yazeed Sawalha | Phase 1 |
| Withdrawn | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma NCT04836832 | Narendranath Epperla | Phase 1 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |